These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38504063)

  • 41. Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study.
    Halvorsen S; Smith JA; Söderdahl F; Thuresson M; Solli O; Ulvestad M; Jonasson C
    BMC Prim Care; 2022 Aug; 23(1):214. PubMed ID: 36008778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.
    Chao TF; Liao JN; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Chung FP; Chen TJ; Lip GYH; Chen SA
    Thromb Haemost; 2019 Jul; 119(7):1162-1170. PubMed ID: 30900222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Percutaneous left atrial appendage occlusion and risk of stroke, hospitalized bleeding and death in Medicare beneficiaries.
    Wang W; Chen LY; Walker RF; Alonso A; Norby FL; Lakshminarayan K; Lutsey PL
    Pharmacoepidemiol Drug Saf; 2024 Apr; 33(4):e5786. PubMed ID: 38565524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Clin Res Cardiol; 2022 Jan; 111(1):23-33. PubMed ID: 33704551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable.
    Piccini JP; Xu H; Cox M; Matsouaka RA; Fonarow GC; Butler J; Curtis AB; Desai N; Fang M; McCabe PJ; Page Ii RL; Turakhia M; Russo AM; Knight BP; Sidhu M; Hurwitz JL; Ellenbogen KA; Lewis WR;
    Circulation; 2019 Mar; 139(12):1497-1506. PubMed ID: 30700141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient Characteristics Associated With Using Transcatheter Left Atrial Appendage Occlusion Versus Oral Anticoagulants for Atrial Fibrillation.
    Lin KJ; Singer DE; Avorn J; Heist EK; Sreedhara SK; Anand P; Zhang Y; Tsacogianis TN; Schneeweiss S
    Circ Cardiovasc Qual Outcomes; 2024 Mar; 17(3):e010279. PubMed ID: 38440888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of Trends in Guideline-Based Oral Anticoagulant Prescription for Patients With Ischemic Stroke and Atrial Fibrillation in China.
    Gu HQ; Yang X; Wang CJ; Zhao XQ; Wang YL; Liu LP; Meng X; Jiang Y; Li H; Liu C; Xiong YY; Fonarow GC; Wang D; Xian Y; Li ZX; Wang YJ
    JAMA Netw Open; 2021 Jul; 4(7):e2118816. PubMed ID: 34323982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A comparison of CAS risk model and CHA
    Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
    [No Abstract]   [Full Text] [Related]  

  • 52. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit.
    Inui TS; Parina R; Chang DC; Inui TS; Coimbra R
    J Trauma Acute Care Surg; 2014 Mar; 76(3):642-9; discussion 649-50. PubMed ID: 24553530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lower rate of major bleeding in very high risk patients undergoing left atrial appendage occlusion: A propensity score-matched comparison with direct oral anticoagulant.
    Magnocavallo M; Della Rocca DG; Vetta G; Mohanty S; Gianni C; Polselli M; Rossi P; Parlavecchio A; Fazia MV; Guarracini F; De Vuono F; Bisignani A; Pannone L; Raposeiras-Roubín S; Lochy S; Cauti FM; Burkhardt JD; Boveda S; Sarkozy A; Sorgente A; Bianchi S; Chierchia GB; de Asmundis C; Al-Ahmad A; Di Biase L; Horton RP; Natale A
    Heart Rhythm; 2024 Aug; 21(8):1267-1276. PubMed ID: 38246567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of CHA2DS2 VASc Score Predictability of Stroke and Systemic Embolization in a Middle Eastern Population with AF: The Jordan Atrial Fibrillation (JoFib) Study.
    Ibdah R; Obeidat O; Khader Y; Al-Nusair J; Abusurrah O; Obeidat A; Obeidat A; Rawashdeh S; Alrabadi N; Obiedat AF; Alnadi NN; Hammoudeh A
    Vasc Health Risk Manag; 2023; 19():255-264. PubMed ID: 37125391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis.
    Joundi RA; Cipriano LE; Sposato LA; Saposnik G;
    Stroke; 2016 May; 47(5):1364-7. PubMed ID: 27026630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
    Noseworthy PA; Yao X; Deshmukh AJ; Van Houten H; Sangaralingham LR; Siontis KC; Piccini JP; Asirvatham SJ; Friedman PA; Packer DL; Gersh BJ; Shah ND
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26541393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.
    van den Ham HA; Klungel OH; Singer DE; Leufkens HG; van Staa TP
    J Am Coll Cardiol; 2015 Oct; 66(17):1851-9. PubMed ID: 26493655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.